Venus Remedies receives Saudi FDA approval for Plerixafor

Business Desk — Fri, 22 May 2026 06:26:15 +0000

Venus Remedies Limited has secured its first Marketing Authorization for Plerixafor from the Saudi Food and Drug Authority (SFDA), marking a significant milestone for the company. This approval represents a strategic move towards high-value specialty injectables in oncology and critical care, moving away from commodity injectable volumes.

Plerixafor, a hematopoietic stem cell mobilizer, is used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is a standard-of-care treatment in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.

Saransh Chaudhary, President of Global Critical Care at Venus Remedies and CEO of Venus Medicine Research Centre, highlighted the importance of this approval, stating, “This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in. The Kingdom has the largest pharmaceutical market in the GCC and one of the fastest-growing oncology and transplant infrastructures in the region.”

The Saudi Arabian pharmaceutical market is projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033, driven by rising chronic disease prevalence and healthcare investment under Vision 2030. The GCC stem cell therapy market was estimated at USD 1.2 billion in 2024, with Saudi Arabia, the UAE, and Qatar as the principal markets.

Aditi K. Chaudhary, President of International Business at Venus Remedies, emphasized the commercial significance of the approval, noting that Saudi Arabia is the most important market in the GCC for specialty oncology. The approval allows Venus Remedies to commercialise Plerixafor 24mg/1.2ml in Saudi Arabia through its existing international business network, focusing on tertiary oncology centres.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Saudi FDA | Business Upturn

Venus Remedies receives Saudi FDA approval for Plerixafor